Savara Pharmaceuticals has made significant progress with its drug Molgramostim, as it achieved statistical significance for primary and secondary endpoints in the IMPALA-2 Phase 3 trial for autoimmune pulmonary alveolar proteinosis (aPAP). The FDA has granted Fast Track designation for Carisma Therapeutics' CT-0525 for HER2-overexpressing solid tumors.
Savara on Wednesday said its experimental drug, molgramostim, met the main goal of a late-stage trial for treating a rare lung disease characterized by a feeling of breathlessness. https://t.co/ed7hjV4f3H https://t.co/ed7hjV4f3H
$SVRA safety good - unmet need for Molgramostim has been granted Orphan Drug, Fast Track, and Breakthrough Therapy designation from the U.S. Food and Drug Administration, Orphan Drug designation from the European Medicines Agency and Innovative https://t.co/NDD0WcoVKR
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) $SVRA https://t.co/JOwEb0TfKn
$SVRA Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2 Pivotal Phase 3 Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) https://t.co/AqHc4Y54u8
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) $SVRA https://t.co/uvFhmgzuel
$SVRA Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) 8am est tomorrow
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors $CARM https://t.co/rpr4Llqqhe